Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive forCD20 and/or CD22

• Subjects with NHL subtypes defined by WHO:

• -Dose-Finding Part: R/R mature B-NHL (except chronic lymphocytic leukemia/smalllymphocytic leukemia [CLL/SLL], Richter's transformation from prior CLL/SLL,Burkitt's lymphoma, and Waldenstrom's macroglobulinemia)

• -Dose-Expansion Part: R/R LBCL, defined as: i. DLBCL; ii. High-grade B-cell lymphomawith MYC and BCL2 and/or BCL6 rearrangements; iii. Transformed FL or transformedmarginal zone lymphoma (MZL); iv. Follicular lymphoma Grade 3B

• R/R disease after at least 2 lines of prior treatment, which must have included:

• -An Anti-CD20 MoAb and an anthracycline for DLBCL, high-grade B-cell lymphoma withMYC and BCL2 and/or BCL6 rearrangements, primary mediastinal large B-cell lymphoma (PMBCL), or transformed FL or MZL

• -An alkylating agent in combination with an anti-CD20 MoAb for FL

• -An anthracycline or bendamustine-containing chemotherapy regimen and a Bruton'styrosine kinase (BTK) inhibitor for mantle cell lymphoma (MCL)

• -Autologous anti-CD19 CAR T-cell therapy, if approved and available for theindicated lymphoma subtype, unless the subject is unable or is ineligible to receiveapproved autologous anti-CD19 CAR T-cell therapy (e.g., fail leukapheresis ormanufacture, unable to wait for manufacture, CD19 negative disease, etc.)

• Autologous hematopoietic stem cells must be available prior to the start of the LDregimen if the subject is considered high-risk for prolonged hematologic toxicity

Exclusion Criteria:

• Prior use of an investigational product (except for cell or gene therapies andMoAbs) within 5 half-lives or within 14 days, whichever is shorter, prior to startof LD regimen

• Previous approved therapy including chemotherapy, biologic (except MoAbs), ortargeted therapy for R/R B-NHL with 5 half-lives or within 14 days, whichever isshorter, prior to start of the LD regimen

• Prior MoAb therapy (approved or investigational) within 30 days prior to start of LD

• Prior systemic immunostimulatory agent within 3 half-lives prior to start of the LDregimen

• Prior cell or gene therapy (approved or investigational) within 6 weeks of the startof LD

• Prior cell or gene therapy (approved or investigational) targeting both CD20 andCD22

• Autologous HSCT infusion within 6 weeks of the start of LD

• Allogeneic HSCT within 3 months of the start of LD, or donor lymphocyte infusionwithin 6 weeks of the start of LD

• Active acute or chronic graft versus host disease (GvHD). Subjects should be off allimmunosuppressive therapies for at least 6 weeks prior to start of LD

• Radiotherapy within 8 weeks (except for palliative radiotherapy for specificon-target lesions) (prior to start of LD regimen)

• Evidence of active central nervous system (CNS) lymphoma or previous CNS involvementof R/R B-NHL

• Presence of an active and clinically relevant CNS disorder

• Daily treatment with >20 mg prednisone or equivalent

• Known active infection, or reactivation of a latent infection, whether bacterial orviral, fungal, mycobacterial, or other pathogens

• History of hypersensitivity to alemtuzumab

• History of neutralizing anti-drug antibody against alemtuzumab

• Any known uncontrolled cardiovascular disease within 3 months of enrollment

• Subjects requiring immunosuppressive treatment

• Major surgery within 28 days prior to start of LD

• Evidence of another uncontrolled malignancy within 2 years prior to Screening (except in situ nonmelanoma skin cell cancers and/or carcinoma in-situ of thecervix)